IL-1 Inhibition in CPPD Save
Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.
The purpose of this analysis is that CPPD preferentially affects older adults; and their comorbidities often limit conventional treatment options.
The metanalysis included 6 studies and 84 patients - from 5 observational and 1 randomized controlled trial. Efficacy of anakinra was suggested by:
- Subjective physician assessments with a positive clinical response rate of 76%
- Significant reduction of VAS scores by -48.12 mm (0-100 scale)
- Significant reduction in CRP levels by - 62.09 mg/L from baseline.
- Reduced TJC (-4.86) and SJC (-3.65)
Adverse reactions included injection site reaction, rash, bacterial pneumonitis, and neutropenia.
Anakinra appears to be effective in acute CPPD flares with a favourable safety profile.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.